奥浦迈：发行股份购买澎立生物100%股权，标的资产过户完成

Group 1 - The company plans to acquire 100% equity of Pengli Bio through a combination of issuing shares and cash payment, along with raising supporting funds [1] - As of January 14, 2026, the equity transfer of Pengli Bio has been completed, with the company directly holding 374,808,585 shares, resulting in a 100% ownership stake [1] - Pengli Bio will become a wholly-owned subsidiary of the company and will be included in the consolidated financial statements [1] Group 2 - The company is required to pay the transaction price, raise supporting funds, and complete business registration changes as part of the acquisition process [1] - Intermediary institutions have confirmed that the transfer procedures for this transaction are legal and valid, with no substantial obstacles anticipated for subsequent matters [1]